ArticleJournal of cosmetic dermatology2025
Dual Benefits of Oral Tranexamic Acid: Reducing Melasma Severity and Inflammation.
Article in Journal of cosmetic dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelasma is a chronic hyperpigmentation disorder influenced by hormonal factors, ultraviolet exposure, and inflammation. While oral tranexamic acid (TXA) is an established treatment, its effects on systemic inflammation remain unclear.
aimsThis study aimed to evaluate the impact of TXA on melasma severity and inflammatory markers.
methodsThis retrospective study included 80 melasma patients and 80 healthy controls. Patients received oral TXA (500 mg/day) for 3 months. Melasma severity was assessed using the Melasma Area and Severity Index (MASI), and inflammatory markers (monocyte, neutrophil, lymphocyte, HDL, MHR, MLR, NLR) were measured at baseline, Month 1, and Month 3. Changes within the melasma group and comparisons with controls were analyzed.
resultsAt 3 months, melasma severity significantly improved, with a 65.1% reduction in MASI (from 12.9 to 4.5, p < 0.001). Monocyte, neutrophil, MHR, MLR, and NLR levels significantly decreased, while HDL and lymphocyte levels increased (p < 0.001). Compared to controls, baseline inflammatory marker levels differed significantly; however, at month 3, only monocyte, MHR, and HDL remained significantly different (p < 0.05). Regression analysis identified NLR and HDL as significant predictors of melasma severity reduction (p = 0.045 and p = 0.011, respectively).
conclusionOral TXA not only improved melasma severity but also modulated systemic inflammation. The association between NLR, HDL, and treatment response suggests their potential as biomarkers for monitoring therapeutic efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.